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Abstract Tyrosine kinases play significant roles in tumor
progression and therapy resistance. Inhibitors of tyrosine
kinases are on the forefront of targeted therapy. For prostate
cancer, tyrosine kinases play an additional role in the
development of castration-resistant disease state, the most
troubling aspect of prostate cancinogenesis which presently
defies any effective treatment. Among the 30 or so tyrosine
kinases expressed in a typical prostate cancer cell, nearly
one third of them have been implicated in prostate
carcinogenesis. Interestingly, most of them channel signals
through a trio of non-receptor tyrosine kinases, Src/Etk/
FAK, referred here as Src tyrosine kinase complex. This
complex has been shown to play a significant role in the
aberrant activation of androgen receptor (AR) mediated by
growth factors (e.g., epidermal growth factor (EGF)),
cytokines (interleukin (IL)-6), chemokines (IL-8), and
neurokines (gastrin-releasing peptide). These factors are
induced and released from the prostate cancer to the stromal
cells upon androgen withdrawal. The Src kinase complex
has the ability to phosphorylate androgen receptor, resulting
in the nuclear translocation and stabilization of un-liganded
androgen receptor. Indeed, tyrosine kinase inhibitors target-
ing Src can inhibit androgen-independent growth of
prostate cancer cells in vitro and in preclinical xenograft
model. While effective in inducing growth arrest and
inhibiting metastasis of castration-resistant tumors, Src
inhibitors rarely induce a significant level of apoptosis.
This is also reflected by the general ineffectiveness of
tyrosine kinase inhibitors as monotherapy in clinical trials.
One of the underlying causes of apoptosis resistance is
“autophagy,” which is induced by tyrosine kinase inhibitors




lead to type II programmed cell death. We demonstrated that
autophagy blockade sensitizes prostate cancer cells toward
Src tyrosine kinase inhibitor. Thus, a combination therapy
based on Src tyrosine kinase inhibitor and autophagy
modulator deserves further attention as a potential treatment
for relapsed prostate cancer.
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Tyrosine Kinases and Prostate Cancer
There is very strong evidence that tyrosine kinases (TKs)
are involved in the growth and metastasis of prostate cancer
(for example [1, 2]). TKs also play key roles in tumor
sensitivity to radiation and chemical-induced apoptosis.
There are a total of 90 human TKs, 58 receptor TKs and 32
non-receptor TKs. Based on our extensive profilings of CaP
cells, we found that on average, about 30 to 40 tyrosine
kinases are expressed in prostate cancer cells [3]. For
example in LNCap, we identified approximately 22
receptor kinases (ErbB1, ErbB2, ErbB3, EphA1, EphB1,
EphB2, EphB3, EphB4, Sky, Mer, Ddr1, Ddr2, PDGFRB,
FGFR2, FGFR3, FGFR4, IGFR, MET, RON, RET, TrkA,
VGFR) and 14 non-receptor tyrosine kinases (SRC, FYN,
YES, LYN, BRK, FER, CSK, ETK, ABL, ARG, JAK1,
TYK2, FAK, PYK2). This is likely an underestimate due to
the sensitivity of the RT-PCR conditions used.
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HER2, erbB3/HER3, FGF-R, insulin-like growth factor
Insulin-like Growth Factor (IGF)-R Met, Ron, Axl, Mer/
Nyk, Kit, RET, and NGF-R have been implicated in prostate
carcinogenesis [4–11]. For instance, EGF and IGF were
shown to activate AR in the absence of androgen and induce
androgen-independent growth of LNCaP cells via Src
pathway [12, 13]. ErbB2/HER2 was reported to be overex-
pressed in androgen independent xenografts and confers
androgen independence [14–17]. It’s elevated expression in
clinically localized prostate cancer identifies metastatic
potential [8]. Likewise, erbB3 is found to be required for
the growth [18] and malignant progession of prostate cancer
[19]. ErbB3 was shown to signal through Src and Etk/
BMX non-receptor tyrosine kinases [18]. We first recog-
nized the diverse pathways and varied effects of erbB2/
erbB3 signaling [20, 21] and found that they also play a
role in channeling signals transmitted by cytokines such as
IL-6. Earlier work also showed that Mer (also called Nyk)
is overexpressed in prostate carcinomas and is able to activate
Src and increase the expression of a host of cytokines and
chemokines ([22] and unpublished work). Recent studies
showed that erbB2/erbB3 as well as Mer signaled through
Ack1 non-receptor tyrosine kinase to phosphorylate and
activate AR [23]. Likewise, Ret overexpression is associated
with high-grade PIN and prostate cancer [24], and was an
activator of Src [25].
Kit, usually found in hematopoietic stem cells, was shown
to be aberrantly expressed as a truncated, activated receptor,
which channels its effects by activating Src [26, 27]. IGF-1
receptor and Met receptor, as well as their ligands have
been implicated in the development of advanced stages of
CaP [27], although the expression of c-met is suppressed by
AR [28, 29] and that of IGF-1R is augmented by androgen
treatment. The ligand for Met, HGF, is involved in drug
resistance [30] and metastasis [31] of CaP, with the former
process involving Src signaling. The transcriptional activa-
tion of IGF-1R by androgen is via Src kinase [32]. These
results suggest that different receptor TKs are implicated in
different sets of CaPs and perhaps at various stages of the
development. There is unlikely a common receptor TK
target for all CaPs [33]. One interesting common thread of
many of these receptor TKs is their ability to activate Src
and its companion TKs, which will be the focus of our
discussion below. While under normal conditions, c-Src
activity is required for channeling multiple signals by these
receptors and regulated by their ligands, elevated and
constitutive Src activity, presumably due to the deregulation
of the receptor activities, is a hallmark of end-stage CRPCs
[34, 35].
Among non-receptor TKs, Src kinase complex, Src, Etk
and FAK, as well as their respective family members figure
prominently in CaPs and will be described separately in the
next section. Little is known about the functions of other
families of non-receptor tyrosine kinases in prostate
carcinogenesis. Ack was found to be able to directly
phosphorylate AR and the Ack/AR complex is recruited
to the ARE sites in the nucleus [36]. C-abl is generally not
expressed or expressed at very low levels in various cell
lines, based on our profile results, and virtually nothing is
known about its role in CaP. Brk, a Src-related kinase, was
shown to have different subnuclear localization in CaP cells
vs normal counterpart, although its role in prostate
carcinogenesis is not clear [37]. For a more detailed
description on non-receptor TK, please see our recent
review [1].
The Src/FAK/Etk Tyrosine Kinase Complex
Src is found to form a complex (or complexes) with another
two TKs FAK and Etk. Src is known to interact with FAK
through SH2–phosphor-Y397 interaction [38, 39] and we
showed that Etk interacts with FAK through PH–FERM
domain interaction [40]. Recent structural data revealed that
FERM domain serves as an autoinhibitory domain of FAK.
Interaction of FERM with other proteins (in this case Etk)
would “open” up the FAK kinase domain and exposes
Y397 for binding to Src, resulting in the activation of both
Src and FAK. We showed Src phosphorylates and activates
Etk [41]. These three kinases, thus, cross-activate one
another, and signal received by one would enhance the
others. That said, these kinases have their own signal
pathways and cellular functions. Their individual connec-
tions to CaP are briefly summarized below.
Although the first oncogene identified, Src’s role in
human malignancies has not been fully appreciated. This
is likely due to the lack of frequent genetic mutations of
this gene in human cancers, although rare mutation has
been reported in colon cancer [42]. Src is ubiquitously
expressed in all prostate cancer samples analyzed ([43], and
unpublished data). Its activity is upregulated in hormone
refractory CaP [35]. In addition to Src, two other Src family
kinases, Fyn and Lyn, are also implicated in CaP
progression [44, 45]. Inhibitors for Src family kinases,
Dasatinib [35] and Saracatinib [46, 47], both arrest CaP cell
growth and migration in vitro with the effect on metastasis
more pronounced in vivo. Strong evidence suggests that
Src is involved in invasion and metastasis especially bone
metastasis [45, 48–50]. Src kinase channel signals through
the conventional Ras/Raf/ERK and PI3K/Akt, but also
activates Stat3, c-myc, and beta-catenin [51–53] and Id-1 [54].
The activation of beta-catenin and Id-1 by Src are relevant to
invasion and metastasis [50, 54] so is its phosphorylation of
FAK [55, 56]. Prostate cells have a propensity to undergo
neuroendocrine differentiation in which Src pathway may be
HORM CANC (2011) 2:38–46 39involved, as recent reports showed that RPTPalpha and
PTP1B, phosphatases which activate Src, induce neuroen-
docrine differentiation [57, 58]. Probably, most relevant to
the development of CRPC (castration-resistant prostate
cancer) is Src’s ability to activate androgen receptor and
translocate AR into the nucleus [59–61] upon activation by
neuropeptides [60, 62, 63] by chemokine IL-8 [64] and by
EGF [44] (Fig. 1). Recently, it was shown that Src directly
phosphorylates, stabilizes, and translocates AR, which is
the major underlying mechanism whereby Src activates
AR’s transcriptional activity and how growth factors and
cytokines activate AR under androgen-depleted conditions
[23, 63, 65, 66]. While Src is able to activate AR and serves
as a coactivator, Src is reciprocally activated by AR and
serves as a downstream effector of AR signaling [67, 68].
The latter is usually referred to as the non-genomic action
of androgen receptor. The above discussion illustrates the role
of Src and family members in prostate carcinogenesis; they
are signal integrators of many growth factors and appropriate
targets for therapy.
FAK was originally identified as an Src substrate, with
subsequent recognition of its role in focal adhesions upon
integrin engagement. Src’s association with and phosphoryla-
tion of FAK increases FAK’s activity which then phosphor-
ylatesahostofproteinsinvolvedincelladhesionandmigration
[38]. They include paxillin and p130cas [69]. FAK is involved
in both the formation and dissolution of the focal adhesion
plaques. FAK inhibitor inhibits the metastasis of PC3 in vivo,
but does not affect its growth and survival [70]. Src
interactions with FAK depend on FAK’s autophosphorylation
of Y397, which is also the binding site for PI3K [71–74].
FAK is overexpressed, activated, and associated with
paxillin in prostatic tissues from CaP patients with
metastases [75, 76]. FAK is activated by neuropeptides
and cell attachment, presumably via the RhoA pathway
[77] .I nt h eT R A M Pm o u s eC a Pm o d e l ,F A Kw a ss h o w n
to be required for androgen-independent formation of
neuroendocrine carcinoma [78].
Etk belongs to the Btk family of TKs, typified by an
N-terminal PH domain, followed by an SH3, SH2, and
kinase domain. It was first reported as Bmx (X-linked bone
marrow kinase) [79]. We independently cloned this kinase
from the CWR22 CaP xenograft [80]. Etk is expressed in
epithelial and endothelial cells, and hence its name. Our lab
has carried out extensive structural and functional studies of
this kinase in CaP [61, 81, 82]. The multidomain structure
of Etk allows it to interact with a variety of signal
molecules, including FAK, Src, RhoA, paxillin, STAT3,
PAK1, PTPD1, VEGFR2, and p53. These molecules are
known to be involved in migration, survival, and angio-
genesis [83]. Through its PH domain, which binds PIP3,
Etk is activated by PI3K [82], but in turn, it is a strong
activator of PI3K pathway [84]. Etk’s autokinase activity is
further augmented by Src phosphorylation at Y566 (the Src
418 equivalent) [41]. We and others showed that Etk
activation can be triggered by a variety of ligands,
including IL-6 [82], bombesin [61], integrin [40], EGF
[85], neuregulin (ErbB2/erbB3 activator) [18], and vascular
Fig. 1 Src kinase complex is
an integrator of signals from
growth factor (EGF), cytokine
(IL-6) to chemokines (GRP and
IL-8). Src, Etk, and FAK cross-
activate one another. Src and Etk
kinases activate AR by direct
phosphorylation leading to
androgen-independent growth;
Src and Etk signals suppress
autophagy and apoptosis
providing survival factors and
together with FAK, they
promote invasion and
metastasis. (GRP) gastrin-
releasing peptide; (G) G protein,
(AR*) aberrantly activated
receptor in the absence of
natural ligand
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VEGF, Etk in turn augments the transcription of VEGF,
providing a strong positive feedback loop during angiogen-
esis. Regarding cellular processes in CaP, Etk is involved in
neuroendocrine differentiation, DNA-damage responses,
hypoxia response, and the development of hormone
refractory tumors. In most cases, it provides strong survival
functions and protects CaP from thapsigargin and photody-
namic therapy-induced apoptosis [87] and from p53-
induced apoptosis through direct interaction with p53
[88], but under certain conditions (e.g., cleaved by
Caspase), it can accelerate apoptosis [89], thus serving as
a gatekeeper for cell survival. Etk was shown to be
overexpressed in CaP and transgenic mice with prostate-
specific expression of Etk developed PIN (prostatic intra-
epithelial neoplasia) [81, 88]. In a recent report, Etk is
shown to be overexpressed in hormone-resistant tumors and
correlates well with the phosphorylation of AR at Y534
site, the phosphoacceptor of Src and Etk kinases (see
below) [90]. Its potential role in the development of CRPC
is shown by its ability to mediate the activation of androgen
receptor by IL-6 [91] and its association, phosphorylation,
and stabilization of androgen receptor in a manner similar
to Src [90]. Etk is found to phosphorylate AR at Y534 and
Y551/552, although not as potent as Src. The detailed
mechanism of AR activation by Etk is not all identical to
Src; for instance, Etk’s association with AR requires
phosphorylated tyrosine 551/552 of AR as anchor sites for
the SH2 domain of Etk. By contrast, the association
between Src and AR rely on the SH3/proline rich domains
of Src and AR, respectively. In addition, the expression of
Etk, but not Src, is in response of androgen deprivation,
thus serving as a natural protector of prostate epithelial
cells. That said, Etk is able to activate FAK and Src, and as
such, the entire complex is involved in CRPC development.
Both Etk and Src are important targets for therapeutic
intervention.
Src Tyrosine Kinase Inhibitors and Prostate Cancer
Therapy
There have been relatively few studies regarding the effects
of Src family kinases inhibitors on CaP cell lines and
xenografts. Dasatinib, a clinically approved thiazole and
pyrimidine-based inhibitor, inhibits Src and Lyn TK at low
nanomolar and effectively suppresses cell adhesion, inva-
sion, and migration of DU145 [43]. This inhibition is
accompanied by the decreased phosphorylation of FAK and
p130cas, and decreased expression of MMP-9. Similarly, a
pyrrolopyrimidine-based Src inhibitor inhibits the growth,
adhesion, motility, and invasion of PC3 [92]. Another
pyrazolo–pyrimidine-based Src inhibitor was shown to
inhibit EGF-induced migration of PC3 [93]. A peptide
inhibitor for Lyn inhibits the in vitro growth of DU145 and
PC3 at low micromolar range. It reduces the tumor volume
of in vivo DU145 explant in nude mice [44]. Thus, the Src
family inhibitors appear to primarily affect migration and
invasion of CaP cells and, to a lesser extent, growth. Our lab
has been studying the efficacy of Saracatinib (AstraZeneca,
formerly AZD0530) [94]a n dP P 2( P f i z e r ) .T h ef o r m e ri sa
drug under clinical development, whereas the latter is
primarily a research tool. We found that the dual use of
PP2 and Saracatinib will help us pinpoint the intended target
better. In androgen-sensitive LNCaP cells, neuropeptides and
EGF are able to activate Src, which in turn, translocates AR
into the nucleus and activates AR target genes, resulting in
androgen-independent growth of the cells [60, 62, 66]. Both
PP2 and Saracatinib treatments reverse this course, resulting
in the growth inhibition of these cells. Likewsie, Dasatinib
was also found to inhibit phosphorylation-activated AR and
androgen-independent growth of CaP under various treat-
ment conditions [23]. Saracatinib inhibits Src family kinases
with an IC50 at a high nanomolar range [46], but also targets
c-abl with less potency. As a result, we initially chose
DU145 for studies of signal attenuation, since this cell line
expresses undetectable levels of c-abl and c-arg. To
understand the general role of Src kinase in prostate cancer
cell biology, the expression and activation were profiled in
CWR22Rv1, DU145, LAPC-4, LNCaP, and PC3, as well as
immortalized prostate epithelial cells such as RWPE-1.
Saracatinib (and similarly PP2) was found to inhibit the
growth of all cell lines with various IC50s. The IC50 for
growth inhibition is around 6 μM for LNCaP, CWR22Rv1,
and DU145, but more than 16 μM for RWPE-1. These
results suggest that Src activation has oncogenic effects in
both androgen receptor-dependent and independent CaPs,
broadening the application of Src inhibitor as a treatment
option for this disease. Both proliferation and migration of
CaP cells are inhibited by the treatment, with little evidence
of apoptosis, based on the appearance of sub-G1 fraction and
caspase activation assays. These inhibitions were accompa-
nied by reduced activation of the ERK1/2 pathway and
reduced expression of β-catenin, c-myc, and cyclin D1,
consistent with their being the downstream targets of Src and
the arrest of growth at the G0/G1 phase. Likewise, the
activation of cell motility factor such as FAK, p130CAS, and
paxillin activation were inhibited. Using an in vivo
androgen-independent xenograft model we developed,
Saracatinib is found to be highly effective in inhibiting
metastasis and to a much lesser extent, tumor growth [62]. It
also exhibits efficacy in inhibiting bone metastasis of
prostate cancer [49]. Despite these benefits, Src inhibitors
do not seem to induce extensive killings of tumor cells,
which compromise its efficacy as an anti-cancer agent. This,
however, is not unique, as most of the tyrosine kinase
HORM CANC (2011) 2:38–46 41inhibitors failed as a monotherapeutic agent. The key
question then is how to enhance the killing effects of the
Src inhibitor specifically and the tyrosine kinase inhibitors in
general.
Src Tyrosine Kinase Inhibitor and Autophagy
To search for the potential cause of apoptosis-resistance in
Src inhibitor-treated cells, we looked for prosurvival signals
still active or even induced after treatment. The most
consistent observation is the induction by Src inhibitors of a
high level of autophagy or macroautophagy, which is
generally viewed as a survival mechanism for cells in
response to stress (nutritional, genotoxic, hypoxia, etc.)
[47]; however, when deregulated, excessive autophagy
leads to the postulated type II programmed cell death.
Modulating autophagy has recently emerged as a possible
means to benefit cancer therapy [95]. Autophagy or
macroautophagy is a catabolic process involving the
degradation of a cell’s own components through the
lysosomal machinery. It begins with the formation of a
double-membrane vesicle, or autophagosome, around a
targeted region of the cell, separating the contents from
the rest of the cytoplasm [96]. The resultant vesicle then
fuses with a lysosome where the contents are degraded. A
series of genes (ATG, autophagy genes), highly conserved
from yeast to mammals, have been implicated in autophagic
processes. For instance, autophagosome is formed by Atg5
and Atg12 conjugation, which then recruits microtubule-
associated protein 1 light chain 3 (LC3), a mammalian
homologue of Atg8. LC3 is cleaved by autophagin (Atg4)
to produce the active cytosolic form LC3-I (18 kDa), which
is then further activated by Atg7, transferred to Atg3, and
posttranslationally modified into the membrane-bounded
active form, LC3-II. The conversion of LC3 isoforms has
been used as a biochemical index in autophagosome
formation, and the number of autophagosomes (presented
as cytoplasmic puncta) provides a semiquantitative measure
of autophagy induction. A standard way of measuring
autophagosome is to incorporate a GFP-LC3 construct into
the cells to be studied. Upon autophagosome formation, the
number of green dots represented by GFP-LC3-II embed-
ded in autophagosome membrane provides a measure of the
beginning step of autophagy. The cellular pathways that
control the autophagic process are not well understood. The
PTEN/PI3-kinase (Class I)/Akt/mTOR/S6K pathway have
been strongly implicated as a negative regulator of
autophagy. It is thought that S6K which regulates protein
translation restricted the translation of some of the Atgs.
Since Src/FAK tyrosine kinase complex associates with the
p85 subunit of PI3 kinase and activates PI3 kinase, Src
activation is expected to suppress autophagy and its
inhibition to cause autophagy. Indeed, Saracatinib or PP2
both inhibit the activation of PI3 kinase downstream
effectors, AKT, mTOR, and S6K [47]. Although the
AKT-mTOR/S6K pathway is likely to contribute to the
suppression of autophagy, it may not be the only one. Src
kinase is known to enhance intracellular energy resource in
favor of survival and growth. For instance, Src activates
AKT and PI3 kinase, which are capable of transporting
GLUT4 to the plasma membrane, resulting in glucose
influx [97, 98]. Recently, Src activation is also seen to be
responsible for thrombin-induced p38MAPK-mediated ac-
tivation of glucose transporter [99]. Likewise, Src is known
to activate HIF-1alpha via the degradation of VHL, an E3
Ub ligase for HIF-1alpha [100], and HIF-1alpha transcrip-
tionally activates GLUT1, also resulting in a rich supply of
glucose [40]. Src inhibition may thus result in glucose
depletion, a condition known to induce autophagy. In
addition, Src may also function to provide an amino acid
balance for the anaerobic glycolysis pathway by increasing
the higher level of glutamine via c-myc, a target gene of Src
[101]. Src inhibition would thus lead to an energy
imbalance, another condition known to induce autophagy.
Thus, Src inhibition may engender a nutritional starvation
condition, leading to autophagy. Finally, as discussed
above, Src inhibition severely compromises AR activity,
which is another potential cause for autophagy. Li et al.
previously showed that androgen depletion which attenu-
ates AR activity results in autopahgy [102]. The exact
mechanism as to how Src inhibitor induces autophagy,
deserves further attention. Our results that Src inhibitor
induces autophagy may not be unique to this system.
Recently, imatinib, an inhibitor of Abl/Src has also been
found to induce a significant level of autophagy, which may
account for its lower efficiency as a monotherapeutic agent
[103].
Autophagy Blockade Enhances the Killing Effects of Src
Inhibitors
Having demonstrated that Src inhibitors induced profound
autophagy in prostate cancer cells, we asked whether
autophagy may contribute to the apoptosis-resistance
observed for tyrosine kinase inhibitors therapy. To test this
thesis, we looked for inhibitors of the autophagy process
and assessed its biological effects when used in combina-
tion with Saracatinib. The idea behind these experiments is
that if autophagy is the barrier to apoptosis, autophagy
inhibitor would enhance the Saracatinib-induced killing of
prostate cancer cells. We chose both a genetic inhibitor,
shRNA against Beclin, a critical ingredient of autophagy
and a pharmacological inhibitor, chloroquine (CQ) for this
study. Chloroquine is a lysotropic agent which disrupts
42 HORM CANC (2011) 2:38–46lysosomal functions by blocking autophagosome fusion and
inability to degrade autophagosome and its cargo. Chloro-
quine is a well-tolerated, clinically approved antimalarial
agent, increasing its prospect as an adjunctive therapy.
Using shRNA against Beclin (Atg8) and CQ, we showed
unambiguously that inhibition of autophagy dramatically
enhanced the apoptosis-inducing effect of Src tyrosine
kinase inhibitor. In vivo testing using PC3 xenograft
confirmed a synergistic effect of Saracatinib and CQ on
the inhibition of tumor growth and enhanced apoptosis in
the tumor tissues. This finding suggests that autophagy
modulator may serve as an effective adjunctive therapeutic
agent to complement tyrosine kinase inhibitor [47].
Conclusion
Since the identification of the first tyrosine kinase profile in
prostate cancer in 1996, numerous studies have implicated
aberrant expression and activation of tyrosine kinases in the
progression of prostate cancer, especially during the
transition to a castration-resistant state. A common signal
integrator of many of these tyrosine kinases is the Src
tyrosine kinase complex, including Src, FAK, and Etk/
BMX tyrosine kinases, which control growth, migration,
survival, and tumor resistance. They are also involved in
the phosphorylation and aberrant activation of androgen
receptor in a ligand-independent manner. Targeting Src
tyrosine kinase complex, thus represents a potential
treatment option for castration-resistant prostate cancer, in
conjunction with hormone therapy. As amply evident
from recent exciting discoveries, tyrosine kinases are
promising targets for cancer therapeutics and are on the
frontline of targeted therapy; however, as monotherapy,
tyrosine kinase inhibitors have not been found to be
particularly effective. One possible reason is their
propensity of inducing autophagy, which confers resis-
tance to apoptosis. Several clinically approved drugs
which block autophagy were shown to enhance cell
killing, when used in combination with tyrosine kinase
inhibitors. We look forward to the future development of
more specific tyrosine kinase inhibitors as well as autophagy
modulators and their applications to castration-resistant
prostate cancers.
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